Get the Stockscreener App
1.38
1.43%
-0.02
After Hours:
1.32
-0.06
-4.35%
Lexaria Bioscience Corp stock is traded at $1.38, with a volume of 98,302.
It is down -1.43% in the last 24 hours and down -5.93% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
98,302
Relative Volume:
0.71
Market Cap:
$24.75M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-3.1364
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+2.99%
1M Performance:
-5.93%
6M Performance:
-51.24%
1Y Performance:
-41.03%
1-Day Range:
$1.3405
$1.48
1-Week Range:
$1.32
$1.5225
52-Week Range:
$1.20
$4.44
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.38 | 24.75M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Corp. Announces Oil Discovery at PPF-12-7 well in Belmont Lake - marketscreener.com
Lifezone Metals (NYSE:LZM) vs. Lexaria Bioscience (OTCMKTS:LXRP) Financial Review - Defense World
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
60,640 Shares in Lexaria Bioscience Corp. (NASDAQ:LEXX) Acquired by Raymond James Financial Inc. - Defense World
Lexaria gets ethics board okay for oral GLP-1 study - MSN
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo
HighTower Advisors LLC Boosts Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Completes Enrollment for Pioneering Drug Delivery Study - TipRanks
Lexaria completes enrollment for diabetes drug study - Investing.com
Lexaria completes enrollment for diabetes drug study By Investing.com - Investing.com UK
Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment - Stock Titan
Lexaria begins human trial for oral diabetes treatment - Investing.com India
Lexaria begins human trial for oral diabetes treatment By Investing.com - Investing.com South Africa
Lexaria Bioscience Begins Human Trials for Oral Liraglutide Alternative - TipRanks
Lexaria's Human GLP-1 Study #5 Begins Dosing - TradingView
Revolutionary Oral GLP-1 Drug Challenges $1.8B Saxenda Market in New Trial - Stock Titan
Lexaria Bioscience (LEXX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Oral tirzepatide capsules match injection efficacy in Lexaria study By Investing.com - Investing.com South Africa
Lexaria’s Oral Capsules Rival Injectable Weight Loss Treatment - TipRanks
Oral tirzepatide capsules match injection efficacy in Lexaria study - Investing.com
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) - ACCESS Newswire
Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound - StreetInsider.com
Revolutionary Oral Alternative to Zepbound Shows 47% Fewer Side Effects in Clinical Trial - StockTitan
Lexaria Bioscience stock hits 52-week low at $1.37 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.37 - Investing.com
Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - TradingView
Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained - StockTitan
Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval - TipRanks
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - TradingView
Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update - StockTitan
Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication - TipRanks
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - WICZ
Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? - StockTitan
Lexaria Bioscience Corp. (NASDAQ:LEXX) Sees Significant Decline in Short Interest - Defense World
Lexaria Bioscience stock hits 52-week low at $1.62 - MSN
Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH - MSN
Lexaria secures new patents for epilepsy treatment tech By Investing.com - Investing.com Nigeria
Lexaria Bioscience stock hits 52-week low at $1.62 By Investing.com - Investing.com South Africa
Lexaria secures new patents for epilepsy treatment tech - MSN
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - WICZ
Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX - StockTitan
Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks
Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway | Users | observernewsonline.com - FinancialContent
Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):